Key result
Ginsenoside Rg3 combined with cyclophosphamide significantly inhibited growth and angiogenesis of ovarian cancer and improved survival time in mice compared to control.
Why the study?
Does the combination of ginsenoside Rg3 and cyclophosphamide inhibit growth and angiogenesis in a mouse model of human ovarian cancer?
Does the combination of ginsenoside Rg3 and cyclophosphamide inhibit growth and angiogenesis in a mouse model of human ovarian cancer?
In a preclinical model of ovarian cancer, the combination of ginsenoside Rg3 and cyclophosphamide synergistically inhibited tumor growth and angiogenesis while improving survival.
This is the authors' abstract. We don't add key points for this paper.
Background Ginsenoside Rg3, the main component isolated from ginseng, inhibits some kinds of tumour growth and angiogenesis. The combination of low dose chemotherapy and antiangiogenesis inhibitors suppresses growth of experimental tumours more effectively than conventional therapy. The effect of this combination on ovarian cancer remains to be evaluated. Therefore, we investigated the synergism of ginsenoside Rg3 and cyclophosphamide (CTX) on growth and angiogenesis of human ovarian cancer. Methods Twenty-eight female athymic mice were divided randomly into 4 groups of 7: ginsenoside Rg3, CTX, ginsenoside Rg3 and CTX combination and control, after being transplanted with ovarian cancer cells (SKOV-3). The mice were given intraperitoneal injection of ginsenoside Rg3 and CTX for the 10 days following inoculation of SKOV-3 cells. The life quality and number of living days of mice were recorded. The size of tumour, tumour inhibitive rate, life elongation rate, proliferating cell nuclear antigen labelling index (PCNALI), expression of vascular endothelial cell growth factor (VEGF) and microvessel density (MVD) of the tumour tissues were estimated. Results Life quality of mice in ginsenoside Rg3 and combined treatment groups were better and number of living days longer than control. Average tumour weights of each treated group were less than control and there was no significant difference among the treated groups. PCNALI of treated groups was lower than control. The MVD value and VEGF expression in treated groups were significantly lower than control and the MVD values of ginsenoside Rg3 and combined treatment groups were lower than that of CTX group. Conclusions Ginsenoside Rg3 significantly inhibited growth and angiogenesis of ovarian cancer when used alone or combined with CTX. Ginsenoside Rg3 and CTX combination reinforced the antitumour effect each other and improved the living quality and survival time of mice with tumour.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in ovarian cancer; leaves open translation of murine anti-tumor effects to human trials.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2007) studied Ovarian cancer (n=28). Ginsenoside Rg3 combined with cyclophosphamide (CTX) vs. Control, ginsenoside Rg3 alone, or CTX alone was evaluated on Tumour growth, angiogenesis, and survival time. Ginsenoside Rg3 combined with cyclophosphamide significantly inhibited growth and angiogenesis of ovarian cancer and improved survival time in mice compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: